PE-22-28 for sale here today for research and education use only. If you are in the research trade and want to buy PE-22-28 click here now.
PE-22-28 is a research peptide that is being tested to improve memory, mood, and learning. It is not for human consumption. The hopeful news is it is hoped one day to help in treating Alzheimer’s, and stroke recovery.
What is PE-22-28?
Alzheimer’s is the third leading cause of death after heart disease and cancer. Currently there is no cure for the disease. The drug PE-22-28 is a new generation of treatments for Alzheimer’s. It has been demonstrated to be better than the drugs that have been around for a long time. At present, there are two Alzheimer’s drugs on the market: Aricept, by Pfizer, and Exelon, by Forest Pharmaceuticals. They all work in different ways. Exelon is based on stimulation of the brain, while Aricept works to reduce the production of proteins called beta-amyloid that build up in the brain.
PE-22-28 For Sale for Studies
Alzheimer’s involves a build-up of beta-amyloid protein, which can cause damage to brain cells, eventually leading to memory loss and cognitive decline.
As more and more people are diagnosed with the disease, many researchers are focused on finding a cure. It is estimated that nearly 6 million Americans have Alzheimer’s, and those numbers are expected to rise.
Alzheimer’s is a disease that affects people’s memories, thinking, behavior, and physical appearance. The majority of people with the disease are over the age of 65. A diagnosis of Alzheimer’s can also be made at any age. With advances in research, medical tests are now available to detect the disease, before symptoms appear. However, diagnosis is only possible after a diagnosis is made through an examination of tissue under a microscope, such as by a neuropathologist.
Research is moving in many directions
Drug Research: Most Alzheimer’s drugs attempt to inhibit the formation of amyloid protein. Drugs may attempt to stop the amyloid proteins from clumping together and forming plaque. The amyloid proteins cause damage to brain cells and interfere with brain functions.
These are a new type of drug being researched. Instead of working with existing amyloid proteins, researchers are designing antibodies (synthetic proteins designed to identify and kill viruses and bacteria) that match the different types of amyloid proteins. The antibodies are given as shots, directly into the blood. They will act like a drug by tagging the amyloid protein and getting them to target the brain to kill them.
A third way of treating Alzheimer’s is gene therapy. The goal of this type of treatment is to make changes in the genes to keep the brain working.
The National Institute on Aging, part of the National Institutes of Health, is currently funding nine Alzheimer’s disease drug trials. The trials are expected to be completed in 2013, but it may take up to three years to publish the results. If a drug is successful, it could help many people.
Currently, most treatments for Alzheimer’s focus on either slowing the progression of the disease or stabilizing patients’ mental abilities.
For more information on research to find a cure for Alzheimer’s, please visit the Alzheimer’s Association’s website.